Detalles de la búsqueda
1.
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.
J Infect Dis
; 227(8): 939-950, 2023 04 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36348617
2.
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector.
J Infect Dis
; 218(4): 633-644, 2018 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-29669026
3.
Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
Int J Clin Pharmacol Ther
; 51(9): 725-37, 2013 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-23924679
4.
Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.
Antimicrob Agents Chemother
; 55(6): 2872-9, 2011 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21464253
5.
Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
J Antimicrob Chemother
; 65(11): 2450-4, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20801782
6.
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
Lancet HIV
; 7(10): e688-e698, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33010242
7.
Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).
Lancet HIV
; 7(6): e410-e421, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32078815
8.
Assessment of etravirine resistance in HIV-1-infected paediatric patients using population and deep sequencing: final results of the PIANO study.
Antivir Ther
; 21(4): 317-27, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26566161
9.
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Relationships of Etravirine in HIV-1-Infected, Treatment-Experienced Children and Adolescents in PIANO.
J Clin Pharmacol
; 56(11): 1395-1405, 2016 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-27060341
10.
Pharmacokinetics of Etravirine Combined with Atazanavir/Ritonavir and a Nucleoside Reverse Transcriptase Inhibitor in Antiretroviral Treatment-Experienced, HIV-1-Infected Patients.
AIDS Res Treat
; 2015: 938628, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25664185
11.
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
J Clin Pharmacol
; 54(5): 563-73, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-25975423
12.
Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virological response.
Antivir Ther
; 18(2): 253-6, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-22951490
13.
Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
J Clin Pharmacol
; 53(1): 41-50, 2013 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-23400742
14.
Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
Antivir Ther
; 17(8): 1571-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22869341
15.
Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.
J Acquir Immune Defic Syndr
; 58(1): 18-22, 2011 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21637112
16.
Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance.
Antivir Ther
; 15(6): 803-16, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-20834093
17.
Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
AIDS Res Hum Retroviruses
; 26(11): 1197-205, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20854144
18.
Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
AIDS Res Hum Retroviruses
; 26(6): 621-4, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20507207
19.
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Antivir Ther
; 15(7): 1045-52, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21041921
20.
Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
AIDS
; 24(4): 503-14, 2010 Feb 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-20051805